Sight Sciences (NASDAQ:SGHT – Get Free Report) and Nano-X Imaging (NASDAQ:NNOX – Get Free Report) are both small-cap healthcare companies, but which is the superior business? We will contrast the two businesses based on the strength of their earnings, profitability, institutional ownership, valuation, dividends, analyst recommendations and risk.
Risk & Volatility
Sight Sciences has a beta of 2.45, suggesting that its share price is 145% more volatile than the S&P 500. Comparatively, Nano-X Imaging has a beta of 1.28, suggesting that its share price is 28% more volatile than the S&P 500.
Earnings and Valuation
This table compares Sight Sciences and Nano-X Imaging”s revenue, earnings per share and valuation.
| Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio | |
| Sight Sciences | $77.36 million | 6.03 | -$38.43 million | ($0.56) | -15.12 |
| Nano-X Imaging | $13.02 million | 3.59 | -$75.02 million | ($2.14) | -0.28 |
Sight Sciences has higher revenue and earnings than Nano-X Imaging. Sight Sciences is trading at a lower price-to-earnings ratio than Nano-X Imaging, indicating that it is currently the more affordable of the two stocks.
Profitability
This table compares Sight Sciences and Nano-X Imaging’s net margins, return on equity and return on assets.
| Net Margins | Return on Equity | Return on Assets | |
| Sight Sciences | -35.69% | -43.39% | -22.86% |
| Nano-X Imaging | -926.05% | -116.93% | -100.67% |
Analyst Recommendations
This is a breakdown of recent ratings for Sight Sciences and Nano-X Imaging, as reported by MarketBeat.com.
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
| Sight Sciences | 1 | 2 | 5 | 0 | 2.50 |
| Nano-X Imaging | 1 | 2 | 2 | 1 | 2.50 |
Sight Sciences currently has a consensus target price of $8.38, indicating a potential downside of 1.12%. Nano-X Imaging has a consensus target price of $4.33, indicating a potential upside of 628.29%. Given Nano-X Imaging’s higher probable upside, analysts plainly believe Nano-X Imaging is more favorable than Sight Sciences.
Institutional and Insider Ownership
55.5% of Sight Sciences shares are owned by institutional investors. Comparatively, 21.5% of Nano-X Imaging shares are owned by institutional investors. 30.4% of Sight Sciences shares are owned by insiders. Comparatively, 7.7% of Nano-X Imaging shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term.
Summary
Sight Sciences beats Nano-X Imaging on 11 of the 14 factors compared between the two stocks.
About Sight Sciences
Sight Sciences, Inc., an ophthalmic medical device company, engages in the development and commercialization of surgical and nonsurgical technologies for the treatment of eye diseases. It operates through two segments, Surgical Glaucoma and Dry Eye. The company's products include OMNI Surgical System, an implant-free glaucoma surgery technology indicated to reduce intraocular pressure in adult patients with primary open-angle glaucoma; and SION Surgical Instrument, a manually operated device used in ophthalmic surgical procedures to excise trabecular meshwork. It also offers TearCare System, a wearable eyelid technology for adult patients with evaporative dry eye disease due to meibomian gland dysfunction, as well as related components. It offers its products through sales representatives and distributors to hospitals, medical centers, and eyecare professionals in the United States. Sight Sciences, Inc. was incorporated in 2010 and is headquartered in Menlo Park, California.
About Nano-X Imaging
Nano-X Imaging Ltd. develops a commercial-grade tomographic imaging device with a digital X-ray source. The company provides teleradiology services and develops artificial intelligence applications to be used in real-world medical imaging applications. Its X-ray source is based on a digital micro-electro-mechanical systems semiconductor cathode. The company's solutions include Nanox Multi Source System comprising Nanox.ARC, a medical tomographic imaging system incorporating its digital X-ray source, and Nanox. CLOUD, a platform which employs a matching engine to match medical images to radiologists that provides image repository, connectivity to diagnostic assistive AI systems, billing, and reporting. It also offers Nanox.MARKETPLACE, which connects imaging facilities with radiologists and enables radiologists to provide, as well as customers to obtain remote interpretations of imaging data; artificial intelligence (AI)-based software imaging solutions to hospitals, health maintenance organizations, integrated delivery networks, pharmaceutical companies, and insurers that are designed to identify or predict undiagnosed or underdiagnosed medical conditions through the mining of data included in images of existing computed tomography scans for osteoporosis and cardiovascular disease; Teleradiology Services, which provide imaging interpretation services for radiology practices, hospitals, medical clinics, diagnostic imaging centers, urgent care facilities; and multi-specialty physician groups, contracts, and radiology readings. The company is headquartered in Petach Tikva, Israel.
Receive News & Ratings for Sight Sciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Sight Sciences and related companies with MarketBeat.com's FREE daily email newsletter.
